Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 at Royal Bank Of Canada
Royal Bank Of Canada raised the price target for Edwards Lifesciences (NYSE:EW) from $89.00 to $95.00, maintaining an "outperform" rating. This suggests a potential upside of 13.85% from the current price. Other analysts have also increased their targets, with an average consensus target price of $90.37. Edwards Lifesciences reported $1.55 billion in revenue for the last quarter, exceeding estimates, and set FY 2025 guidance at 2.560-2.620 EPS. The stock traded at $83.44, with a market cap of $48.99 billion and a P/E ratio of 12.01.
Edwards Lifesciences (NYSE:EW - Get Free Report) had its price target lifted by stock analysts at Royal Bank Of Canada from $89.00 to $95.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical research company's stock. Royal Bank Of Canada's price objective would suggest a potential upside of 13.85% from the company's current price.
- 3 Healthcare Pathbreakers With Long-Term Tailwinds
A number of other research analysts have also recently commented on EW. Wells Fargo & Company upped their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a research note on Thursday, August 7th. The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences in a research note on Friday. Robert W. Baird set a $83.00 target price on Edwards Lifesciences in a research note on Friday. Evercore ISI upped their target price on Edwards Lifesciences from $88.00 to $92.00 and gave the company an "outperform" rating in a research note on Friday. Finally, Canaccord Genuity Group upped their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $90.37.
Get Edwards Lifesciences alerts:
Check Out Our Latest Research Report on EW
Edwards Lifesciences Trading Down 0.0%
- Can financial, healthcare, energy stocks rise as rates stay high?
EW stock traded down $0.04 during midday trading on Friday, reaching $83.44. 2,655,850 shares of the company traded hands, compared to its average volume of 4,529,455. Edwards Lifesciences has a 52-week low of $64.89 and a 52-week high of $87.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The business has a 50 day moving average of $77.57 and a 200-day moving average of $76.79. The firm has a market capitalization of $48.99 billion, a price-to-earnings ratio of 12.01, a P/E/G ratio of 3.97 and a beta of 1.05.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the business posted $0.67 earnings per share. The company's quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts expect that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.
Insider Buying and Selling at Edwards Lifesciences
- Why Analysts Say GE's Healthcare Spinoff Has $20 Upside
In related news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.29% of the company's stock.
Institutional Investors Weigh In On Edwards Lifesciences
Institutional investors have recently added to or reduced their stakes in the business. Econ Financial Services Corp purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $889,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $1,760,000. Czech National Bank boosted its stake in shares of Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock valued at $11,214,000 after purchasing an additional 7,917 shares during the period. Finally, Mirova US LLC boosted its stake in shares of Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company's stock valued at $229,257,000 after purchasing an additional 1,054,301 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.
Edwards Lifesciences Company Profile
(Get Free Report)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Further Reading
- Five stocks we like better than Edwards Lifesciences
- Find and Profitably Trade Stocks at 52-Week Lows
- Comfort Systems Is the AI Data Center Stock Beating NVDA, AVGO, & AMD
- What is the Dogs of the Dow Strategy? Overview and Examples
- Cameco's $80 Billion U.S. Nuclear Deal Changes Everything
- What is the Euro STOXX 50 Index?
- NU Stock: U.S. Bank License May Be the Next Growth Catalyst
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Edwards Lifesciences Right Now?
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
